Inovio (INO) Receives Upgrade to Buy: Reasons Behind the Decision
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy INO?
Source: NASDAQ.COM
Inovio Pharmaceuticals Upgrade: Inovio Pharmaceuticals has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.
Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.
Earnings Estimates: Analysts have raised their earnings estimates for Inovio, with a 5% increase in the Zacks Consensus Estimate over the past three months, reflecting an improvement in the company's underlying business.
Market Positioning: The upgrade places Inovio in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price increases driven by positive earnings revisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.740
Low
3.00
Averages
7.33
High
13.00
Current: 1.740
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the implications for the INO-3107 Biologics License Application, leading to investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its strong capabilities in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, being ranked first in 2017 for the number of securities class action settlements, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel to avoid inexperienced intermediaries, ensuring they receive the best representation and support in the class action process.
See More
Inovio Pharmaceuticals Faces Securities Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky, LLP alerts investors that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is facing a securities class action lawsuit, with the court setting April 7, 2026, as the deadline for lead plaintiff applications, covering the period from October 10, 2023, to December 26, 2025.
- FDA Approval Misrepresentation: The lawsuit alleges that management repeatedly exaggerated the prospects for FDA accelerated approval and priority review for Inovio's lead product candidate, despite lacking sufficient information to justify the BLA's eligibility for accelerated approval.
- Market Reaction: When the FDA ultimately accepted the BLA for standard review instead of accelerated review, the market reacted negatively, indicating that the commercial implications of accelerated approval were significant and formed a core part of the company's overall investment thesis.
- Investor Transparency: Joseph E. Levi, Esq. emphasized that investors deserve transparency regarding material risks that could affect their investments, particularly in the biotechnology sector where adequate regulatory pathway disclosures are fundamental.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses.
- Legal Counsel Recommendation: Investors are encouraged to select law firms with a successful track record; Rosen Law Firm is recognized for its achievements in securities class actions, having recovered over $438 million for investors in 2019 alone.
- Next Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the lawsuit, emphasizing that until the class is certified, investors must choose legal counsel to protect their interests.
See More
Faruqi & Faruqi Investigates Potential Claims Against Inovio
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Inovio Pharmaceuticals due to possible false statements made during securities transactions from October 10, 2023, to December 26, 2025, which may have harmed investors' rights.
- FDA Review Update: Although Inovio submitted its Biologics License Application for INO-3107 on December 29, 2025, the FDA indicated that insufficient information was provided to justify accelerated approval, posing regulatory challenges that could delay product launches.
- Significant Stock Decline: Following the FDA announcement, Inovio's stock plummeted by 24.45% to close at $1.73 per share, reflecting a pessimistic market outlook on the company's future prospects, which may further erode investor confidence.
- Investor Rights Protection: Faruq & Faruq LLP reminds investors that April 7, 2026, is the deadline to apply as lead plaintiff in the class action lawsuit, emphasizing the importance of seeking legal support to protect their rights.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device manufacturing and overstated prospects for the INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this area.
- Investor Guidance: Investors are advised to select counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action process.
See More
Inovio Pharmaceuticals Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, that they must apply to be lead plaintiff by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the implications for the INO-3107 Biologics License Application, leading to investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked number one for securities class action settlements in 2017, showcasing its strong capabilities in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, being ranked first in 2017 for the number of securities class action settlements, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel to avoid inexperienced intermediaries, ensuring they receive the best representation and support in the class action process.
See More
Inovio Pharmaceuticals Faces Securities Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky, LLP alerts investors that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is facing a securities class action lawsuit, with the court setting April 7, 2026, as the deadline for lead plaintiff applications, covering the period from October 10, 2023, to December 26, 2025.
- FDA Approval Misrepresentation: The lawsuit alleges that management repeatedly exaggerated the prospects for FDA accelerated approval and priority review for Inovio's lead product candidate, despite lacking sufficient information to justify the BLA's eligibility for accelerated approval.
- Market Reaction: When the FDA ultimately accepted the BLA for standard review instead of accelerated review, the market reacted negatively, indicating that the commercial implications of accelerated approval were significant and formed a core part of the company's overall investment thesis.
- Investor Transparency: Joseph E. Levi, Esq. emphasized that investors deserve transparency regarding material risks that could affect their investments, particularly in the biotechnology sector where adequate regulatory pathway disclosures are fundamental.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses.
- Legal Counsel Recommendation: Investors are encouraged to select law firms with a successful track record; Rosen Law Firm is recognized for its achievements in securities class actions, having recovered over $438 million for investors in 2019 alone.
- Next Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the lawsuit, emphasizing that until the class is certified, investors must choose legal counsel to protect their interests.
See More
Faruqi & Faruqi Investigates Potential Claims Against Inovio
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Inovio Pharmaceuticals due to possible false statements made during securities transactions from October 10, 2023, to December 26, 2025, which may have harmed investors' rights.
- FDA Review Update: Although Inovio submitted its Biologics License Application for INO-3107 on December 29, 2025, the FDA indicated that insufficient information was provided to justify accelerated approval, posing regulatory challenges that could delay product launches.
- Significant Stock Decline: Following the FDA announcement, Inovio's stock plummeted by 24.45% to close at $1.73 per share, reflecting a pessimistic market outlook on the company's future prospects, which may further erode investor confidence.
- Investor Rights Protection: Faruq & Faruq LLP reminds investors that April 7, 2026, is the deadline to apply as lead plaintiff in the class action lawsuit, emphasizing the importance of seeking legal support to protect their rights.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device manufacturing and overstated prospects for the INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this area.
- Investor Guidance: Investors are advised to select counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action process.
See More
